Full-Time

Associate Director

Patient-Centered Outcomes, Patient-Centered Outcomes

Jazz Pharmaceuticals

Jazz Pharmaceuticals

1,001-5,000 employees

Biopharmaceuticals focused on neuroscience and oncology

Compensation Overview

$172k - $258k/yr

Palo Alto, CA, USA + 4 more

More locations: London, UK | Cambridge, UK | Philadelphia, PA, USA | Carlsbad, CA, USA

Remote

10–20% domestic and international travel is required.

Bachelor's, Master's, PhD

Category
Biology & Biotech
Required Skills
Forecasting
SAP Products
Word/Pages/Docs
Biostatistics
Excel/Numbers/Sheets

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Requirements
  • A minimum of three years’ experience working in PCOs/COAs environments and experience in evidence generation, HEOR, RWE, Medical Affairs, or Market Access in a pharmaceutical company and/or consultancy is preferred.
  • Experience in Oncology is essential.
  • Experience in leading strategically, communicating with impact, and creating a strong, inclusive, energizing culture is required.
  • Excellent organizational skills are required.
  • Proven proficiency in Microsoft Word, Excel, PowerPoint, Smartsheet, and SAP is required.
  • Proven proficiency with virtual collaboration tools such as Microsoft Teams and Zoom is required.
  • Effective written and oral communication, interpersonal, problem-solving, and facilitation skills are required.
  • Ability to prioritize and multitask, work effectively with little or no direction, and build collaborative relationships with management, partners, and peers is required.
  • Ability to work in a highly energetic, flexible, and fast-paced environment is required.
  • Willingness to engage in self-development to keep up to date with changes in the COA field is required.
  • Bachelor’s degree is essential.
Responsibilities
  • Support and lead the development and execution of COA strategies and tactical plans across the Oncology and Neuroscience therapeutic areas globally in collaboration with cross-functional teams.
  • Support and lead collaboration with functional and senior leadership to build awareness about the potential role of COAs in product development, commercial development, indication identification, and other activities.
  • Build trust and lines of communication with internal collaborators across the US and EUR/International regions, including Patient Advocacy, Procurement, Finance, Biostats, Clinical, Medical Affairs, HEOR, Commercial, Market Access, and Legal.
  • Work with the Head of PCO and cross-functional teams to identify COA measurement approaches using existing or de novo measures and advise COA endpoint strategies.
  • Define the scope of work for and manage relationships with vendors and key opinion leaders for timely completion of COA projects while ensuring quality, consistency, and compliance.
  • Support and lead request for proposal/request for quotation development to procure COA services.
  • Attend project team meetings to track project timelines and deliverables.
  • Perform project administrative functions.
  • Serve as the point of contact for financial communications, including invoicing, payment, and accrual discussions.
  • Establish and maintain storage of study documents.
  • Serve as PV Project Lead/Adverse Event Monitor.
  • Coordinate and secure internal Jazz approvals, yielding study materials ready for ethics submission.
  • Secure fair market value approval for healthcare professional or patient engagement.
  • Support forecasts and manage PCO project budget needs, including FTEs, travel, and education/professional development.
  • Track and manage the status of PCO proposals, projects, and other activities.
  • Serve as a Pharmacovigilance System Master File key stakeholder for adverse-event-generating studies for ex-US Jazz marketed products.
Desired Qualifications
  • Experience working in PCOs/COAs environments and in evidence generation, HEOR, RWE, Medical Affairs, or Market Access in a pharmaceutical company and/or consultancy.
  • Experience in Neuroscience.
  • Master’s degree or PhD.
  • 10–20% domestic and international travel is required.

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue reached $1.21 billion, and full-year guidance rose to $4.60-$4.75 billion.
  • Ziihera approval on August 25, 2026 opens a $3 billion-$5 billion peak-sales opportunity.
  • Zepzelca and Xywav posted strong 2026 growth, validating Jazz's oncology and sleep franchises.

What critics are saying

  • Lupin, Teva, and Tris challenge Xywav and Xyrem, threatening 2027-2033 economics.
  • Granules settled in March 2026 with launch rights under confidential terms, pressuring Xywav pricing.
  • Jazz took on Actio for $820 million upfront; ABS-1230 still faces clinical and regulatory failure.

What makes Jazz Pharmaceuticals unique

  • Xywav owns narcolepsy and idiopathic hypersomnia through FDA orphan exclusivity until July 2027.
  • Epidiolex gives Jazz rare epilepsy scale, with durable U.S. brand recognition since 2021 GW acquisition.
  • Ziihera launch on August 25, 2026 expands Jazz into HER2-positive gastroesophageal cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
StockTitan
Aug 27th, 2026
Jazz Pharmaceuticals prices upsized $1.1B exchangeable notes offering with $225M share repurchase

Jazz Pharmaceuticals has priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion. The offering, conducted through its wholly-owned subsidiary Jazz Investments I Limited, is expected to close on 31 August 2026. The notes will mature on 15 September 2032 and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share. This represents a 42.5% premium above the last reported sale price on 26 August 2026. The company will use net proceeds of approximately $1,079 million for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase approximately $225 million of its ordinary shares from note purchasers at $249.29 per share, using existing cash on hand.

Yahoo Finance
Aug 26th, 2026
Jazz Pharmaceuticals launches Ziihera for HER2-positive cancer with $3B–$5B peak sales outlook

Jazz Pharmaceuticals has launched Ziihera in the US following FDA approval for first-line treatment of HER2-positive, unresectable or metastatic gastroesophageal adenocarcinoma. The drug can be used with tislelizumab and chemotherapy, or with chemotherapy alone for certain patients. In the Phase III HERIZON-GEA-01 trial, Ziihera-based regimens reduced the risk of disease progression or death by 35%. The triplet regimen extended median overall survival to 26.4 months, a 28% reduction in death risk versus trastuzumab. Jazz estimates the US addressable market at 3,000–4,000 patients annually and raised Ziihera's peak sales outlook to $3 billion–$5 billion. The company plans to leverage existing commercial infrastructure whilst pursuing additional cancer indications and international regulatory filings.

Yahoo Finance
Aug 11th, 2026
Jazz Pharmaceuticals Q2 revenue beats estimates at $1.21B, ups guidance to $4.68B

Jazz Pharmaceuticals reported a strong second quarter with revenue of $1.21 billion, beating analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion from $4.38 billion. CEO Renée Galá attributed the performance to strong demand for flagship products like Xywav and Epidiolex, alongside accelerating uptake of new oncology therapies. Operating margin improved to 20.5%, up from negative 65.6% in the prior year quarter. However, adjusted earnings per share of $5.71 missed analyst expectations of $6.18. During the earnings call, analysts focused on Epidiolex's growth drivers, Xywav's sustainability amid potential generic competition, and zanidatamab's upcoming approval prospects.

Yahoo Finance
Aug 11th, 2026
Jazz Pharma raises 2026 guidance on record Q2 revenue of $1.2B, up 16%

Jazz Pharmaceuticals reported record second quarter revenue of $1.2 billion, representing 16% year-over-year growth. The company raised its full-year revenue guidance based on strong first-half performance. Chief executive officer Renée Galá attributed the results to execution across the company's diversified portfolio and sustained demand for its commercial products. The company is preparing to launch zanidatamab, with a PDUFA date of 25 August for treatment of first-line HER2-positive metastatic gastroesophageal adenocarcinoma. The earnings call included updates from senior leadership, including chief commercial officer Samantha Pearce, global head of research and development Robert Iannone, and chief financial officer Philip Johnson. Jazz Pharmaceuticals highlighted progress on its long-term value creation priorities whilst maintaining focus on current commercial operations.

Yahoo Finance
Aug 10th, 2026
Jazz Pharmaceuticals to acquire Actio Biosciences for $820M upfront, adding KCNT1+ epilepsy therapy

Jazz Pharmaceuticals has agreed to acquire Actio Biosciences for $820 million upfront and up to $500 million in contingent payments. The deal adds ABS-1230, a clinical-stage precision therapy for KCNT1+ epilepsy, to Jazz's rare epilepsy portfolio. KCNT1+ epilepsy is a rare genetic condition affecting approximately 2,500 patients in the United States. Patients typically experience dozens to hundreds of seizures daily that resist standard medications. Around 80% of cases begin in infancy, with many children unable to reach basic developmental milestones. There are currently no FDA-approved therapies for KCNT1+ epilepsy. ABS-1230 recently showed meaningful seizure reductions in an early clinical trial. The ongoing Phase 1b/2a KYRON trial is designed as the registrational study supporting US new drug application submission.